Dar Dowlatshahi profile picture

Contact Information

Dar Dowlatshahi, MD PhD FRCP(C)
613-761-5073

Wendy Lamont
Clinical Administrative Assistant
613-761-4709
FAX: 613-761-5360
Patient related inquiries

ORCID logo https://orcid.org/0000-0003-1379-3612

Dar Dowlatshahi

Senior Scientist, Neuroscience
Ottawa Hospital Research Institute
Professor, Medicine, School of Epidemiology and Public Health
University of Ottawa
Stroke Neurologist, Medicine, Neurology
Ottawa Hospital
Vice Chair of Research, Department of Medicine
University of Ottawa
ORCID, https://orcid.org/0000-0003-1379-3612

Research Interests

1) Intracerebral Hemorrhage (ICH). I am interested in how acute ICH behaviour relates to clinical symptoms and recovery, and how volume, location & morphology can influence early hematoma expansion, ventricular rupture, and final outcome.

2) Neuroimaging & hyper-acute stroke. I believe multi-modal imaging can optimize acute stroke therapy; findings on CTA and CTP can guide therapeutic decision-making, and expand our current treatment windows.

3) Acute stroke therapy. Our group actively participates in multicentre trials of novel therapies for both ischemic stroke and ICH.

Brief Biography

Dr. Dar Dowlatshahi obtained his MD and PhD from McMaster University (Hamilton, Canada), completed a residency in Neurology at the University of Ottawa, Canada, followed by a Stroke Fellowship at the University of Calgary, Canada. He is a Professor of Medicine and Epidemiology at the University of Ottawa, a Senior Scientist at the Ottawa Hospital Research Institute, the Vice Chair Research of the Department of Medicine, and a Stroke Neurologist at the Ottawa Hospital.  Dr. Dowlatshahi has over 300 peer-review publications on the topic of stroke and intracerebral hemorrhage and holds a Tier 1 Clinical Research Chair at the University of Ottawa. His research focuses on early hematoma expansion.

Selected Publications

Gotesman RD, Niznick N, Dewar B, Fergusson DA, Mallick R, Shorr R, Shamy M, Dowlatshahi D. The prevalence of non-contrast CT imaging abnormalities in reversible cerebral vasoconstriction syndrome: A systematic review and meta-analysis. PLoS One. 2024 Mar 11;19(3):e0295558.

Lun R, Siegal D, Ramsay T, Stotts G, Dowlatshahi D. Synthetic data in cancer and cerebrovascular disease research: A novel approach to big data. PLoS One. 2024 Feb 7;19(2):e0295921.

Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, Barber PA, Bazan R, Buck BH, Butcher KS, Camden MC, Campbell BCV, Casaubon LK, Catanese L, Chatterjee K, Choi PMC, Clarke B, Dowlatshahi D, Ferrari J, Field TS, Ganesh A, Ghia D, Goyal M, Greisenegger S, Halse O, Horn M, Hunter G, Imoukhuede O, Kelly PJ, Kennedy J, Kenney C, Kleinig TJ, Krishnan K, Lima F, Mandzia JL, Marko M, Martins SO, Medvedev G, Menon BK, Mishra SM, Molina C, Moussaddy A, Muir KW, Parsons MW, Penn AMW, Pille A, Pontes-Neto OM, Roffe C, Serena J, Simister R, Singh N, Spratt N, Strbian D, Tham CH, Wiggam MI, Williams DJ, Willmot MR, Wu T, Yu AYX, Zachariah G, Zafar A, Zerna C, Hill MD; TEMPO-2 investigators. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial. Lancet. 2024 Jun 15;403(10444):2597-2605.

Yogendrakumar V, Mayer SA, Steiner T, Broderick JP, Dowlatshahi D. Exploring Hematoma Expansion Shift With Recombinant Factor VIIa: A Pooled Analysis of 4 Randomized Controlled Trials. Stroke. 2023 Dec;54(12):2990-2998.

Dowlatshahi D, Jamal M, Raposo N. Hematoma Tolerance: Location Matters. Stroke. 2023 Jun;54(6):1558-1559.

Lun R, Shaw JR, Roy DC, Siegal D, Ramsay T, Chen Y, Dowlatshahi D. Effect modification of age and hypertension on cancer and prevalence of self-reported stroke - A cross-sectional study. Cancer Med. 2023 Jun;12(11):12518-12523.

Dowlatshahi D, Lum C, Menon BK, Bharatha A, Dave P, Puac-Polanco P, Blacquiere D, Stotts G, Shamy M, Momoli F, Thornhill R, Lun R, Torres C. Aetiology of extracranial carotid free-floating thrombus in a prospective multicentre cohort. Stroke Vasc Neurol. 2023 Jun;8(3):194-196.

Lun R, Roy DC, Hao Y, Deka R, Huang WK, Navi BB, Siegal DM, Ramsay T, Fergusson D, Shorr R, Dowlatshahi D. Incidence of stroke in the first year after diagnosis of cancer-A systematic review and meta-analysis. Front Neurol. 2022 Sep 20;13:966190.

Lun R, Dhaliwal S, Zitikyte G, Roy DC, Hutton B, Dowlatshahi D. Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis. JAMA Neurol. 79.2 (2022):141-148.

Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB, Thirunavukkarasu S, Khosravani H, Appireddy R, Moreau F, Gubitz G, Tkach A, Catanese L, Dowlatshahi D, Medvedev G, Mandzia J, Pikula A, Shankar J, Williams H, Field TS, Manosalva A, Siddiqui M, Zafar A, Imoukhuede O, Hunter G, Demchuk AM, Mishra S, Gioia LC, Jalini S, Cayer C, Phillips S, Elamin E, Shoamanesh A, Subramaniam S, Kate M, Jacquin G, Camden MC, Benali F, Alhabli I, Bala F, Horn M, Stotts G, Hill MD, Gladstone DJ, Poppe A, Sehgal A, Zhang Q, Lethebe BC, Doram C, Ademola A, Shamy M, Kenney C, Sajobi TT, Swartz RH; AcT Trial Investigators. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022 Jul 16;400(10347):161-169.

Yogendrakumar V, Ramsay T, Menon BK, Qureshi AI, Saver JL, Dowlatshahi D. Hematoma Expansion Shift Analysis to Assess Acute Intracerebral Hemorrhage Treatments. Neurology. 2021 Aug 24;97(8):e755-e764.

Lun R, Yogendrakumar V, Walker G, Shamy M, Fahed R, Qureshi A, Dowlatshahi D. Revised intracerebral hemorrhage expansion definitions: Relationship with care limitations. Int J Stroke. 2021 Aug;16(6):640-647.

Hill MD, Goyal M, Menon BK, Nogueira RG, McTaggart RA, Demchuk AM, Poppe AY, Buck BH, Field TS, Dowlatshahi D, van Adel BA, Swartz RH, Shah RA, Sauvageau E, Zerna C, Ospel JM, Joshi M, Almekhlafi MA, Ryckborst KJ, Lowerison MW, Heard K, Garman D, Haussen D, Cutting SM, Coutts SB, Roy D, Rempel JL, Rohr AC, Iancu D, Sahlas DJ, Yu AYX, Devlin TG, Hanel RA, Puetz V, Silver FL, Campbell BCV, Chapot R, Teitelbaum J, Mandzia JL, Kleinig TJ, Turkel-Parrella D, Heck D, Kelly ME, Bharatha A, Bang OY, Jadhav A, Gupta R, Frei DF, Tarpley JW, McDougall CG, Holmin S, Rha JH, Puri AS, Camden MC, Thomalla G, Choe H, Phillips SJ, Schindler JL, Thornton J, Nagel S, Heo JH, Sohn SI, Psychogios MN, Budzik RF, Starkman S, Martin CO, Burns PA, Murphy S, Lopez GA, English J, Tymianski M; ESCAPE-NA1 Investigators. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet. 2020 Mar 14;395(10227):878-887.

Diseases, conditions and populations of interest





Research and clinical approaches